Please login to the form below
Immunomic Therapeutics
This page shows the latest Immunomic Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Astellas extends phase III programme for Rydapt rival gilteritinib
Oncology is a key priority for Astellas, and along with the Ganymed buy, it signed a wide-ranging immuno-oncology deal with Potenza Therapeutics last year, and followed it up with ... a $300m licensing deal with Immunomic Therapeutics.
Latest news
-
Astellas buys Ganymed to boost immuno-oncology pipeline
Last year it signed a wide-ranging immuno-oncology deal with Potenza Therapeutics and followed it up with a $300m licensing deal with Immunomic Therapeutics.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2015
Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... Collaboration, licence. 325. Immunomic Therapeutics/ Astellas Pharma. LAMP-vax products for allergic diseases incl
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- Sanofi halts recruitment for trials assessing MS treatment
- Eli Lilly to make bebtelovimab commercially available to US states from August
- The patient voice – the value of patient-reported outcomes in HTA
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- ONS records a continued fall in UK COVID-19 infections
- Powering Rapid Cognitive Analysis with AI
- How the Royal Society’s EiR programme can help to drive UK innovation
- BMS and 2seventy bio announce positive results for multiple myeloma treatment
- Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy
- Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases
- JCVI publishes statement on London polio vaccination strategy
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris
- EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
- FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
